Overview

Efficacy & Safety Study of Bilateral IVT Injection of GS010 in LHON Subjects Due to the ND4 Mutation for up to 1 Year

Status:
Active, not recruiting

Trial end date:
2024-06-30

Target enrollment:

Participant gender:

Summary

The goal of this clinical trial is to assess the safety and efficacy of GS010, a gene therapy, in improving the retina functional & structural outcomes in subjects with LHON due to the G11778A ND4 mitochondrial mutation when vision loss duration is present up to one year.

Phase:

Phase 3

Details

Lead Sponsor:

GenSight Biologics

Treatments:

Central Nervous System Depressants